The TP53 tumor-suppressor gene is mutated in >40% of human tumors, and patients with Li–Fraumeni syndrome with germline mutations are predisposed to a spectrum of tumors that includes several lethal childhood sarcomas, such as rhabdomyosarcoma and osteosarcoma (Gröbner et al., 2018; Guha and Malkin, 2017). Here, TP53 is linked to neoplasm.